Althin shows sales growth in 1995 despite US knock
This article was originally published in Clinica
Executive Summary
Despite a sales decline in the US - Althin Medical's largest market - the Swedish dialysis company reported an increase in 1995 revenues of 12% when adjusted for exchange rate moves. Last year, Althin lost its main US customer when National Medical Care reduced the number of dialysis equipment suppliers to two - Fresenius and Baxter.
You may also be interested in...
Dr Reddy’s Knocked Back On Rituximab In US
Dr Reddy’s has received a complete response letter from the US FDA, knocking back its proposed rituximab biosimilar rival to Rituxan.
Sandoz And Samsung Celebrate Stelara Rival’s EU Approval
Sandoz and Samsung Bioepis have received final European Commission approval for their partnered Pyzchiva biosimilar rival to Stelara. But with European competition on ustekinumab due to kick off in just a matter of months, further applicants are also waiting in the wings.
Second EU MDR Notified Body Designated In France
Four years after the designation of the first notified body in France under the Medical Device Regulation, AFNOR Certification has been named too.